Login to Your Account



Financings Roundup

Sorbent's Series B Swells to $53M, Runway Through 2013

By Catherine Shaffer


Tuesday, July 5, 2011
Sorbent Therapeutics Inc. expanded its Series B financing round by $36 million, for a deal total of $53 million. The proceeds will support Phase II development of its cardiovascular candidate, CLP1001. The financing round was led by new investor Novartis Venture Funds, and was joined by Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem. Novartis attributed its interest in Sorbent to CLP1001's promising clinical data.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription